Vital Signs - The Analyst's Perspective - May 2015 Issue

USD 450.00

* Required Fields

USD 450.00


Be the first to review this product

This issue of Vital Signs, released on June 8, 2015, discusses cholesterol lowering drugs from Amgen and Sanofi/Regeneron, LabCorp's new offering of direct-to-consumer testing, Apple's foray into collecting genetic information from users, and Danaher's acquisition of Pall.

Table of Contents

Vital Signs - The Analyst's Perspective - May 2015 Issue Vital Signs - May 2015 IssueThis month's issue

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.